# OnCo record nct06936644 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06936644/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06936644", "NCT06936644" ;
  schema:name "A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation"@en ;
  schema:description "A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06936644/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06936644> ;
  onco:status "planned" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/fulzerasib/>, <https://onco.cc/drugs/ivonescimab/> .